Insider trade

Corcept Therapeutics (CORT)CEO sold ~$1.07M

Joseph K Belanoff, CEO at Corcept Therapeutics, sold ~$1.07M of Corcept Therapeutics shares.

~$1.07M
Approx. value · 14K sh @ $74.20: 2.76M
Holds after · shares reported

Traded: Nov 5, 2025
Filed: Nov 6, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

Sep 10, 2025InsiderDirector sold ~$159K of CORT shares in the open market
Oct 6, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 6, 2025, Gillian Cannon, Ph.D., notified the Board of Directors (the “Board”) of Corcept Therapeutics Incorporated (the “Company”) of her resignation from the Board, effective as of October 10, 2025 (the “Effective Date”).”
Oct 7, 2025InsiderOfficer sold ~$1.8M of CORT shares in the open market
Oct 10, 2025Company filing · Form 8-K · Agreement endedEnded an important agreement
Oct 10, 2025InsiderDirector sold ~$193K of CORT shares in the open market
Nov 3, 2025Insider · 3 peopleInsiders: 3 sales (~$2.7M)
Nov 4, 2025Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
Nov 5, 2025 · this disclosureInsiderCEO sold ~$1.07M of CORT shares in the open market

What came next

Nov 5, 2025Insider · 2 peopleInsiders: 5 sales (~$2.6M)
Nov 25, 2025Insider · 1 personInsiders: 2 sales (~$728K)
Dec 1, 2025Insider · 3 peopleInsiders: 3 sales (~$5.2M)
Dec 2, 2025Insider · 1 personInsiders: 2 sales (~$1.6M)
Jan 6, 2026InsiderOfficer sold ~$704K of CORT shares in the open market
Feb 3, 2026InsiderOfficer sold ~$817K of CORT shares in the open market
Feb 24, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors

View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Corcept Therapeutics

For Corcept Therapeutics, OQRO holds 64 insider filings (SEC Form 4 or Form 144) and 5 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CORT page.

Other recent filings by Joseph K Belanoff, Chief Executive Officer

The full history of Joseph K Belanoff, Chief Executive Officer is on the profile page.

How this filing works

Other disclosures at Corcept Therapeutics

Everything OQRO holds on this company is on its CORT page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO Pro Already have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data